Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TYRA-300
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : Tyra Biosciences
Deal Size : $100.0 million
Deal Type : Public Offering
Tyra Biosciences Wants to Bank $100 M for an IPO
Details : TYRA-300, a selective inhibitor of FGFR3, for the treatment of FGFR3-driven cancers initially for patients with bladder cancer who are resistant to FGFR therapies. TYRA-300 has demonstrated potency against both wild-type and resistant FGFR3 targets.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 20, 2021
Lead Product(s) : TYRA-300
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Tyra Biosciences
Deal Size : $100.0 million
Deal Type : Public Offering
Reset All
